Transaction DateRecipientSharesTypePriceValue
22nd December 2020Partners L P/Il Bvf509,410Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf11,278Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf97,615Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf1,944Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf654,215Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf15,166Conversion of derivative$0.00
17th December 2020Capital Management, Llc Aquilo250,000Open or private sale$18.81$4,703,225.00
16th December 2020Capital Management, Llc Aquilo14,933Open or private sale$18.62$278,034.54
9th December 2020Partners L P/Il Bvf166,194Open or private sale$18.00$2,991,492.00
9th December 2020Partners L P/Il Bvf239,274Open or private sale$18.00$4,306,932.00
Pieris Pharmaceuticals
Pieris Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas.


Ticker: PIRS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1583648
Employees: 127
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $44 M (-28%)
Assets, Current: $92 M (-19%)
Property, Plant and Equipment, Net: $21 M (0%)
Other Assets, Noncurrent: $2 M (-37%)
Assets: $118 M (-16%)
Accounts Payable, Current: $4 M (-24%)
Accrued Liabilities, Current: $6 M (-40%)
Liabilities, Current: $18 M (-32%)
Liabilities: $71 M (-20%)
Common Stock, Value, Issued: $52 Th (-5%)
Common Stock, Shares, Issued: $52 M (-5%)
Additional Paid in Capital, Common Stock: $230 M (1%)
Retained Earnings (Accumulated Deficit): $183 M (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-46%)
Stockholders' Equity (Parent): $47 M (0%)
Liabilities and Equity: $118 M (-16%)
Research and Development: $11 M (-52%)
General and Administrative Expenses: $5 M (-48%)
Operating Income/Loss: $5 M (-45%)